

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/441,140
		Filing Date	November 16, 1999
		First Named Inventor	Beka SOLOMON
		Group Art Unit	4642 1647
		Examiner Name	G. Bansal NICHOLS
Sheet 1	of 2	Attorney Docket Number	SOLOMON=1R

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
CSO	AE	5,750,349	A	Suzuki et al	05-12-1998	
	AF	5,753,624	A	McMichael et al	05-19-1998	
	AG	5,851,996	A	Kline	12-22-1998	
CSO	AH	5,955,317	A	Suzuki et al	09-21-1999	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Number		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office ³	Number			
CSO	AI	WO	95/31996	A1	MILKHAUS LABORATORY	11-30-1995

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
CSO	AJ	DELIMASTRO et al, "Immunogenicity of filamentous phage displaying peptide mimotopes after oral administration", <u>Vaccine</u> 15(11):1276-1285 (1997)	
	AK	DODART et al, "Immunization reverses memory deficits without reducing brain A β burden in Alzheimer's disease model", <u>Nat Neurosci</u> 5(5):452-457 (2002) (published online April 8, 2002, pp. 1-6)	
	AL	JANUS et al, "A β peptide immunization reduces behavioral impairment and plaques in a model of Alzheimer's disease", <u>Nature</u> 408(6815):979-982 (2000)	
	AM	MANOUTCHARIAN et al, "Phage Displayed Biomolecules As Preventive and Therapeutic Agents", <u>Curr Pharm Biotechnol</u> 2(3):217-223 (2001)	
	AN	MORGAN et al, "A β peptide vaccination prevents memory loss in an animal model of Alzheimer's disease" <u>Nature</u> 408(6815):982-985 (2000)	
	AO	SEUBERT et al, "Isolation and quantification of soluble Alzheimer's β -peptide from biological fluids", <u>Nature</u> 359(6393):325-327 (1992)	
	AP	Elan Internet Press Release, "Elan and AHP provide an update on the phase 2A Clinical Trial of AN-1792", January 18, 2002 (www.elan.com/NewsRoom)	
CSO	AQ	Elan Internet Press Release, "Elan and Wyeth provide update on status of Alzheimer's collaboration", March 2002 (www.elan.com/NewsRoom)	

Examiner Signature	<i>G. Nichols</i>	Date Considered	7/30/02
--------------------	-------------------	-----------------	---------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

RECEIVED

AUG 28 2002

TECH CENTER 600/29